MARCIA FOURNIER FOUNDER AND CEO OF BIOARRAY THERAPEUTICS TO JOIN GOVERNOR PATRICK ON INNOVATION ECONOMY MISSION TO BRAZIL
Part of exciting opportunity to promote Massachusetts to new markets, create jobs
BOSTON -- NOVEMBER, 16, 2011 – BIOARRAY’s Founder and CEO Marcia Fournier will join Massachusetts Governor Deval Patrick and a coalition of business executives, academic leaders and government officials on the Massachusetts-Brazil Innovation Economy Mission 2011 this December to pursue job growth and economic development partnerships between Massachusetts and Brazil.Marcia will contribute her expertise in cancer research and development of molecular diagnostics to help the delegation assess economic development opportunities that encourage Brazilian companies to invest and create jobs in Massachusetts. During the trip, Marcia will take part in roundtables, company visits and meetings with government and business officials."The Innovation Economy Mission to Brazil will enhance BIOARRAY’s position to carry out its mission of bringing molecular diagnostics to the clinic to help patients and doctors by improving breast cancer detection and treatments” said Marcia. “As the Brazilian economy continues to grow, this opportunity will provide a forum to develop key collaborations with companies and universities, bring investments as well as boost exchange of scientific information and markets”.
“We are committed to competing for every job in every corner of the Commonwealth, and the world,” said Governor Patrick. “To continue our recovery, we need to position Massachusetts for success in growing markets like Brazil, to drive job growth and catalyze international investment.”
From December 4-9, 2011, Marcia will join the Governor’s delegation during stops in Brasilia, Sao Paulo and Rio de Janiero, visiting Brazilian companies, universities and government leaders -- highlighting all that Massachusetts has to offer to Brazil.
In 2010, bilateral trade between Massachusetts and Brazil topped $475 million – representing more than $396 million in exports to Brazil and more than $80 million in imports to Massachusetts.
The missionwill explore growth opportunitieswithin Massachusetts’ innovation-based industries and areas of common interest between the state’s established and emerging partners in Brazil.
About BIOARRAY Therapeutics:
BIOARRAY is a Boston-based biotech company focused on eliminating unnecessary chemotherapy treatments by providing personalized prediction of chemotherapy response. Specifically, the company is developing a molecular test that accurately predicts the likelihood that a breast cancer will respond to conventional chemotherapy treatments. The test predicts for all subtypes of breast cancer and for multiple chemotherapy treatments. Because doctors currently lack tools to identify which treatment will work best for a particular patient, BIOARRAY’s test can improve treatment decisions, eliminate chemotherapy treatments that have little or no therapeutic benefit, and significantly reduce treatment costs. BIOARRAY’s team has developed an innovative tissue-based discovery approach that identifies better biomarkers and as a result, their test is more flexible and powerful than other tests under development. For a young company, BIOARRAY has a strong, committed core team as well as an impressive scientific advisory board. The company is a Silver Winner in this year’s 2011 MassChallenge competition, which had over 700 companies competing.
BIOARRAY has a rich pipeline of genomic products in development based on its unique biological approach and genomic platform.
BIOARRAY was founded in 2009 by scientists from the Dana-Farber Cancer Institute and Lawrence Berkeley National Laboratory and is based in Boston, Massachusetts.
About BIOARRAY’s CEO:
Dr Fournier is trained in biology with 10+ years of experience in cancer research and a Founder and CEO of BIOARRAY Therapeutics. In addition to BIOARRAY, she currently serves on multiple scientific committees for grant and peer-review journals as well as presenting in business innovation forums. Dr Fournier most recently held a position at GlaxoSmithKline, Oncology Center of Excellence for Drug Discovery. Dr Fournier’s work as a doctoral fellow at the Dana-Farber Institute and postdoctoral at Berkeley lead to seminal publications on biomarker discovery. Dr. Fournier holds a Ph.D. and a M.Sc. in molecular biology from the Biophysics’ Institute at the Federal University of Rio de Janeiro, Brazil.